TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Alteration of Articles of Association of the Company07-08-2023
07-08-2023
Torrent Pharma Q1 net profit rises 7% at Rs 378 crore
Revenue for the first quarter of the current fiscal rose to Rs 2,591 crore as against Rs 2,347 crore in the year-ago period, Torrent Pharma said in a statement.07-08-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to reg 30 of SEBI(LODR), 2015 we would like to inform that Company has commenced commercial operations of its new Oral Oncology facility at Bileshwarpura close to Indrad, Gujarat. The facility will cater to all our markets. please take the information on record07-08-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceeding of 50th Annual General meeting of the Company held on 07.08.202307-08-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
Presentation to analyst on unaudited consolidated financial result for quarter ended 30.06.202307-08-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Financial Result For Quarter Ended 30Th June, 2023
Board has at its meeting held today approved, inter alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with limited review report of the Company for the quarter ended 30th June, 2023. The said financial results are enclosed herewith.07-08-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Submission / Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Financial Results For Quarter Ended 30Th June, 2023
Submission / Intimation u/r 30 of SEBI (LODR) Regulation, 2015 - Financial Result for quarter ended 30th June, 202307-08-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates31-07-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate Share Certificates27-07-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In furtherance to our earlier intimation dated 31st July, 2021, we wish to inform you that the National Company Law Tribunal, Mumbai vide its order dated 22nd June, 2023, the certified copy of which was received on 19th July, 2023, has approved the Scheme of Amalgamation for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these companies are subsidiaries of Aarogya Bharat Digital LLP (earlier known as DigiHealth Technologies LLP), which in turn is a wholly-owned subsidiary of ABCD Technologies LLP. The Company owns 6.45% interest ABCD Technologies LLP. The above is for your information and record.20-07-2023